title: The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: a meta-analysis.
abstract: The prognostic significance of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation on Glioblastoma multiforme (GBM) remains controversial. A meta-analysis of published studies investigating the effects of MGMT promoter methylation on both progression-free survival (PFS) and overall survival (OS) among GBM patients was performed. A total of 2,986 patients from 30 studies were included in the meta-analysis. In all, the frequency of MGMT promoter methylation was 44.27 %. Five studies undertook univariate analyses and nine undertook multivariate analyses of MGMT promoter methylation on PFS. The pooled hazard ratio (HR) estimate for PFS was 0.72 (95 % CI 0.55-0.95) by univariate analysis and 0.51 (95 % CI 0.38-0.69) by multivariate analysis. The effect of MGMT promoter methylation on OS was evaluated in 15 studies by univariate analysis and 14 studies by multivariate analysis. The combined HR was 0.67 (95 % CI 0.58-0.78) and 0.49 (95 % CI 0.38-0.64), respectively. For GBM patients treated with Alkylating agent, the meta-risk remained highly significant by both univariate (HR = 0.58; 95 % CI 0.42-0.79) and multivariate analysis (HR = 0.42; 95 % CI 0.29-0.60). This study showed that MGMT promoter methylation was associated with better PFS and OS in patients with GBM regardless of therapeutic intervention, and associated with longer OS in GBM patients treated with alkylating agents.
authors: Department of Forensic Medicine, Zun Yi Medical College, Zun Yi, 563003, People's Republic of China, newman-zhk@163.com.
authors: Kui
authors: K
authors: Zhang
authors: Xiao-qin
authors: XQ
authors: Wang
authors: Bin
authors: B
authors: Zhou
authors: Lin
authors: L
authors: Zhang
mesh_terms: D001932:Brain Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D002986:Clinical Trials as Topic; D019175:DNA Methylation; D015254:DNA Modification Methylases / Q000235:genetics*; D045643:DNA Repair Enzymes / Q000235:genetics*; D005909:Glioblastoma / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D006801:Humans; D011379:Prognosis; D011401:Promoter Regions, Genetic / Q000235:genetics*; D025521:Tumor Suppressor Proteins / Q000235:genetics*
chemical_list: D025521:Tumor Suppressor Proteins; D015254:DNA Modification Methylases; C515491:MGMT protein, human; D045643:DNA Repair Enzymes
references: Clin Transl Oncol. 2011 Sep;13(9):677-85
references: 21865140
references: J Neurooncol. 2011 Apr;102(2):311-6
references: 20686820
references: Cancer. 2011 Apr 15;117(8):1721-30
references: 21472719
references: BMC Genomics. 2010 Dec 14;11:701
references: 21156036
references: Neuroimage. 2012 Jan 16;59(2):908-16
references: 22001163
references: Neurosurgery. 2009 Nov;65(5):866-75; discussion 875
references: 19834398
references: Neuro Oncol. 2010 Mar;12(3):283-8
references: 20167816
references: Neurol Med Chir (Tokyo). 2010;50(9):713-9
references: 20885105
references: J Neurooncol. 2012 Jan;106(2):243-50
references: 21792731
references: Cancer. 2009 Oct 15;115(20):4783-94
references: 19637364
references: J Natl Cancer Inst. 1959 Apr;22(4):719-48
references: 13655060
references: Control Clin Trials. 1986 Sep;7(3):177-88
references: 3802833
references: Cancer Res. 1999 Feb 15;59(4):793-7
references: 10029064
references: Stat Med. 2002 Jun 15;21(11):1539-58
references: 12111919
references: Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):661-7
references: 22414280
references: Lancet Oncol. 2008 Jan;9(1):29-38
references: 18082451
references: Radiat Oncol. 2011 Sep 13;6:115
references: 21910919
references: Bioessays. 1994 Nov;16(11):833-9
references: 7840761
references: Clin Cancer Res. 2005 Jul 15;11(14):5167-74
references: 16033832
references: J Neurooncol. 2010 May;97(3):311-22
references: 19841865
references: Hum Pathol. 2009 Jul;40(7):934-41
references: 19356788
references: Neuroepidemiology. 2009;32(1):21-9
references: 18997474
references: Biometrics. 1994 Dec;50(4):1088-101
references: 7786990
references: Cancer. 2009 Aug 1;115(15):3512-8
references: 19514084
references: N Engl J Med. 2000 Nov 9;343(19):1350-4
references: 11070098
references: Acta Neurochir (Wien). 2009 Nov;151(11):1349-58
references: 19730774
references: N Engl J Med. 2005 Mar 10;352(10):997-1003
references: 15758010
references: Cancer. 2012 Sep 15;118(18):4545-54
references: 22359215
references: Neuropathology. 2009 Aug;29(4):443-9
references: 19170894
references: Pathology. 2011 Jan;43(1):17-23
references: 21240060
references: Oncol Rep. 2010 Jun;23(6):1655-62
references: 20428822
references: Clin Cancer Res. 2004 Mar 15;10(6):1871-4
references: 15041700
references: Science. 2008 Sep 26;321(5897):1807-12
references: 18772396
references: Int J Oncol. 2009 Jun;34(6):1743-8
references: 19424593
references: Acta Neuropathol. 2007 Aug;114(2):97-109
references: 17618441
references: Int J Cancer. 2011 Aug 1;129(3):659-70
references: 21425258
references: Lancet Oncol. 2009 May;10(5):459-66
references: 19269895
references: Clin Cancer Res. 2006 Aug 1;12(15):4738-46
references: 16899625
references: J Clin Oncol. 2009 Dec 1;27(34):5743-50
references: 19805672
references: Int J Clin Oncol. 2010 Aug;15(4):352-8
references: 20232102
references: J Neurosurg. 2008 Dec;109 Suppl:106-17
references: 19123896
references: Cancer Res. 1993 Jul 15;53(14):3416-20
references: 8324751
references: J Neurol Neurosurg Psychiatry. 2011 Apr;82(4):441-6
references: 20861061
references: Cancer Res. 1991 Aug 15;51(16):4131-4
references: 1868433
references: N Engl J Med. 2008 Jul 31;359(5):492-507
references: 18669428
references: Med Oncol. 2012 Jun;29(2):1292-6
references: 21394635
references: PLoS One. 2012;7(3):e33449
references: 22428052
references: Mutat Res. 2000 Apr;462(2-3):83-100
references: 10767620
references: Neuro Oncol. 2011 Feb;13(2):195-202
references: 21075779
references: BMC Cancer. 2010 Feb 18;10:48
references: 20167086
references: Int J Cancer. 2012 Sep 15;131(6):1342-50
references: 22139906
references: Curr Opin Oncol. 2007 Nov;19(6):606-11
references: 17906460
references: Stat Med. 1998 Dec 30;17(24):2815-34
references: 9921604
references: N Engl J Med. 2005 Mar 10;352(10):987-96
references: 15758009
references: Cancer Sci. 2011 Dec;102(12):2186-90
references: 21895872
references: Neuro Oncol. 2010 Feb;12(2):116-21
references: 20150378